Correction to: Association between plasma levels of PCSK9 and the presence of coronary artery disease in Japanese

被引：0
|
作者：
Daisuke Nose
Yuhei Shiga
Yoko Ueda
Yoshiaki Idemoto
Kohei Tashiro
Yasusnori Suematsu
Takashi Kuwano
Ken Kitajima
Keijiro Saku
Shin-ichiro Miura
机构：
[1] Fukuoka University School of Medicine,Department of Cardiology
[2] Fukuoka University School of Medicine,Department of Molecular Cardiovascular Therapeutics
来源：
Heart and Vessels | 2019年 / 34卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
In the original publication of the article, Tables 1, 2 and 3 was published incorrectly. Unnecessary inequality symbols were added to all the numbers in the ‘p value’ of Tables 1, 2 and 3. The correct tables should be as follows,
引用
收藏
页码：29 / 32
页数：3
相关论文
共 50 条
  • [31] Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease
    Nozue, Tsuyoshi
    Hattori, Hiroaki
    Ogawa, Kazuyuki
    Kujiraoka, Takeshi
    Iwasaki, Tadao
    Hirano, Tsutomu
    Michishita, Ichiro
    LIPIDS IN HEALTH AND DISEASE, 2016, 15 : 1 - 7
  • [32] Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease
    Tsuyoshi Nozue
    Hiroaki Hattori
    Kazuyuki Ogawa
    Takeshi Kujiraoka
    Tadao Iwasaki
    Tsutomu Hirano
    Ichiro Michishita
    Lipids in Health and Disease, 15
  • [33] Low PCSK9 plasma level is an independent predictor of coronary atherosclerotic burden in patients with stable coronary artery disease
    Caselli, C.
    Ragusa, R.
    Del Turco, S.
    De Graaf, M.
    Basta, G.
    Scholte, A.
    De Caterina, R.
    Neglia, D.
    EUROPEAN HEART JOURNAL, 2019, 40 : 3780 - 3780
  • [34] Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition
    Musunuru, Kiran
    ANNUAL REVIEW OF MEDICINE, VOL 72, 2021, 2021, 72 : 447 - 458
  • [35] ASSOCIATION OF APOLIPOPROTEINS PLASMA LEVELS WITH PCSK9 IN TYPE 2 DIABETES MELLITUS
    Baudin, Bruno
    Nekaies, Ymene
    Baudin, Bruno
    Kelbousi, Sami
    Sakly, Mohsen
    Attia, Nebil
    ATHEROSCLEROSIS, 2017, 263 : E273 - E274
  • [36] PCSK9 GENETIC VARIANTS IN PATIENTS WITH CORONARY ARTERY DISEASE - A PILOT STUDY
    Ashavaid, T. F.
    Bane, A.
    Ponde, C. K.
    Rajani, R. M.
    Pillai, S.
    ATHEROSCLEROSIS, 2018, 275 : E224 - E225
  • [37] Effect of PCSK9 inhibition on platelet reactivity in coronary artery disease patients
    Galli, Lukas
    Ondracek, Anna
    Seidl, Veronika
    Hofbauer, Thomas
    Zedan, Yasmin
    Schrutka, Lore
    Krychtiuk, Konstantin
    Lang, Irene M.
    Speidl, Walter
    Distelmaier, Klaus
    WIENER KLINISCHE WOCHENSCHRIFT, 2019, 131 : 372 - 373
  • [38] Association between Plasma Sestrin2 Levels and the Presence and Severity of Coronary Artery Disease
    Kishimoto, Yoshimi
    Aoyama, Masayuki
    Saita, Emi
    Ikegami, Yukinori
    Ohmori, Reiko
    Kondo, Kazuo
    Momiyama, Yukihiko
    DISEASE MARKERS, 2020, 2020
  • [39] Plasma PCSK9 levels and atherosclerosis burden in the coronary arteries of patients undergoing coronary angiography
    Panahi, Y.
    Ghahrodi, M. S.
    Jamshir, M. S.
    Safarpour, M. A.
    Pirro, M.
    Bianconi, V.
    Farahani, M. M.
    Banach, M.
    Sahebkar, A.
    EUROPEAN HEART JOURNAL, 2019, 40 : 472 - 472
  • [40] Joint Genetic Inhibition of PCSK9 and CETP and the Association With Coronary Artery Disease A Factorial Mendelian Randomization Study
    Cupido, Arjen J.
    Reeskamp, Laurens F.
    Hingorani, Aroon D.
    Finan, Chris
    Asselbergs, Folkert W.
    Hovingh, G. Kees
    Schmidt, Amand F.
    JAMA CARDIOLOGY, 2022, 7 (09) : 955 - 964
12345